Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Respiratory Syncytial Virus Vaccines Market Projected to Surpass $113 Billion by 2035 – SNS Insider

globenewswire.com
GSK GSK is mentioned as a major company in the RSV vaccines market. The article discusses the overall market growth and technological advancements, but does not provide specific sentiment for GSK's performance or prospects. PFE Pfizer is mentioned as a major company in the RSV vaccines market. The article discusses the overall market growth and technological advancements, but does not provide specific sentiment for Pfizer's performance or prospects. AZN AstraZeneca is mentioned as a major company in the RSV vaccines market. The article discusses the overall market growth and technological advancements, but does not provide specific sentiment for AstraZeneca's performance or prospects.

Respiratory Syncytial Virus Vaccines Market Projected to Surpass $113 Billion by 2035 – SNS Insider Austin, United States, April 27, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Respiratory Syncytial Virus Vaccines Market size valued at USD 3.48 billion in 2025 and is projected to surpass USD 113.41 billion by 2035 and grow at a CAGR of 41.68% over 2026-2035. Due to increased awareness of RSV-related difficulties in infants, the elderly, and immunocompromised populations, the market for respiratory syncytial virus (RSV) vaccines is expanding quickly.

Market Size and Forecast:

Get a Sample Report of Respiratory Syncytial Virus Vaccines Market: https://www.snsinsider.com/sample-request/9113

Rising Adoption of mRNA Vaccine Technology to Boost Market Growth Globally

The demand for the respiratory syncytial virus (RSV) vaccine is expected to increase significantly as a result of the mRNA vaccine. You can safely repeat doses, and you can develop quick, strong, and targeted immunity. More worldwide access is made possible by the solution's affordability and scalability. The effective use of COVID-19 vaccines has boosted investment and confidence, which has fueled the development and uptake of RSV vaccines, expanding the market and improving protection for high-risk groups.

Major Respiratory Syncytial Virus Vaccines Market Companies Listed in the Report are

Segmentation Analysis:

By Technology

Monoclonal Antibodies are the dominant segment in the global respiratory syncytial virus vaccines market, with a 42.97% market share in 2025, as they have demonstrated strong efficacy in preventing severe RSV among infants globally. The Recombinant Protein + Adjuvant segment is emerging as the fastest growing with a CAGR of 42.05% in the respiratory syncytial virus vaccines market trend, due to its high immunogenicity and safety, especially in the elderly.

By Type

In 2025, the Passive Immunization segment dominated the Respiratory Syncytial Virus Vaccines Market trend with a 78.80% market share as it can protect high-risk infants using monoclonal antibodies including Beyfortus (nirsevimab). The Preventive Vaccines segment is the fastest growing aspect of the respiratory syncytial virus vaccines market analysis, as approvals for vaccination for the elderly and pregnant women, such as Arexvy and Abrysvo, have been on the rise.

By Population

Adults held a dominant share in the respiratory syncytial virus vaccines market of 72.22% in 2025, owing to the burden of disease among elderly people. Infants and children are emerging as the fastest-growing segment in the respiratory syncytial virus vaccines market with the highest CAGR of 42.36% as they are at high risk of severe RSV disease.

By Channel

Hospital & Retail Pharmacies are the largest segment of end users for the respiratory syncytial virus vaccines industry, owing to their extensive availability and administration of adult and pediatric vaccinations. The Government Suppliers segment is witnessing the highest growth in the global respiratory syncytial virus vaccines industry.

Do you have any specific queries or need any customization research on Respiratory Syncytial Virus Vaccines Market, make an Enquiry Now: https://www.snsinsider.com/enquiry/9113

Respiratory Syncytial Virus Vaccines Market Key Segments

By Technology

By Type

By Population

By Channel

Regional Insights:

The U.S. Respiratory Syncytial Virus Vaccines Market was valued at USD 0.85 billion in 2025 and is expected to reach USD 27.22 billion by 2035, growing at a CAGR of 41.43% over 2026-2035. Large pharmaceutical companies dominate the U.S. respiratory syncytial virus vaccine market with to significant R&D investment, advancements in mRNA and monoclonal antibody platforms, and regulatory expertise.

The Asia-Pacific is the largest and fastest-growing region in the global respiratory syncytial virus (RSV) vaccines industry respiratory syncytial virus vaccines share, with a market share of 32.15% and a CAGR of 42.14% owing to its large population, high RSV burden in children, aging population, and growing investment in healthcare.

The respiratory syncytial virus vaccine industry's second-largest revenue-generating area is North America. The key variables include early regulatory adoption, the availability of a sophisticated healthcare infrastructure, and increased awareness among the target demographic.

Recent Developments:

Exclusive Sections of the Report (The USPs):

Buy an Enterprise-User PDF of Respiratory Syncytial Virus Vaccines Market Outlook Report 2026-2035: https://www.snsinsider.com/checkout/9113

Respiratory Syncytial Virus Vaccines Market Report Scope

Related Market Reports

Respiratory Syncytial Virus Diagnostics Market

Respiratory Syncytial Virus (RSV) Therapeutics Market

Influenza Diagnostics Market

Human Metapneumovirus (hMPV) Diagnostics Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.